Aprea Therapeutics (NASDAQ:APRE) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock.

Aprea Therapeutics Stock Performance

Shares of Aprea Therapeutics stock opened at $3.67 on Wednesday. Aprea Therapeutics has a 12 month low of $2.15 and a 12 month high of $8.85. The stock’s fifty day moving average price is $3.35 and its 200-day moving average price is $3.46.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.11. The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. On average, equities research analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Insider Activity at Aprea Therapeutics

In related news, Director Marc Duey sold 6,462 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $4.58, for a total transaction of $29,595.96. Following the sale, the director now owns 233,651 shares of the company’s stock, valued at $1,070,121.58. This trade represents a 2.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up approximately 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest position. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.